Fujian Wanchen Biotechnology Co. Ltd (300972) - Net Assets
Based on the latest financial reports, Fujian Wanchen Biotechnology Co. Ltd (300972) has net assets worth CN¥3.42 Billion CNY (≈ $501.01 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.76 Billion ≈ $1.57 Billion USD) and total liabilities (CN¥7.34 Billion ≈ $1.07 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Fujian Wanchen Biotechnology Co. Ltd balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.42 Billion |
| % of Total Assets | 31.82% |
| Annual Growth Rate | 39.58% |
| 5-Year Change | 290.81% |
| 10-Year Change | N/A |
| Growth Volatility | 40.29 |
Fujian Wanchen Biotechnology Co. Ltd - Net Assets Trend (2019–2025)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Fujian Wanchen Biotechnology Co. Ltd market capitalisation.
Annual Net Assets for Fujian Wanchen Biotechnology Co. Ltd (2019–2025)
The table below shows the annual net assets of Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2025. Also explore 300972 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.55 Billion ≈ $373.26 Million |
+74.55% |
| 2024-12-31 | CN¥1.46 Billion ≈ $213.84 Million |
+110.02% |
| 2023-12-31 | CN¥695.81 Million ≈ $101.82 Million |
+3.49% |
| 2022-12-31 | CN¥672.36 Million ≈ $98.39 Million |
+3.01% |
| 2021-12-31 | CN¥652.71 Million ≈ $95.51 Million |
+62.91% |
| 2020-12-31 | CN¥400.65 Million ≈ $58.63 Million |
+16.19% |
| 2019-12-31 | CN¥344.82 Million ≈ $50.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fujian Wanchen Biotechnology Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1095.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.17 Billion | 79.00% |
| Other Components | CN¥311.44 Million | 21.00% |
| Total Equity | CN¥1.48 Billion | 100.00% |
Fujian Wanchen Biotechnology Co. Ltd Competitors by Market Cap
The table below lists competitors of Fujian Wanchen Biotechnology Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nexstar Broadcasting Group Inc
NASDAQ:NXST
|
$4.82 Billion |
|
Sonoco Products Company
NYSE:SON
|
$4.83 Billion |
|
Rail Vikas Nigam Limited
NSE:RVNL
|
$4.83 Billion |
|
Hengdian Group DMEGC Magnetics Co Ltd
SHE:002056
|
$4.83 Billion |
|
Celanese Corporation
NYSE:CE
|
$4.82 Billion |
|
Crocs Inc
NASDAQ:CROX
|
$4.82 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
$4.81 Billion |
|
SIG Combibloc Group AG
SW:SIGN
|
$4.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fujian Wanchen Biotechnology Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,098,154,172 to 1,483,249,505, a change of 385,095,334 (35.1%).
- Net income of 1,344,598,815 contributed positively to equity growth.
- Dividend payments of 175,769,910 reduced retained earnings.
- Other factors decreased equity by 783,733,571.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.34 Billion | +90.65% |
| Dividends Paid | CN¥175.77 Million | -11.85% |
| Other Changes | CN¥-783.73 Million | -52.84% |
| Total Change | CN¥- | 35.07% |
Book Value vs Market Value Analysis
This analysis compares Fujian Wanchen Biotechnology Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 56.60x to 21.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.00 | CN¥169.54 | x |
| 2020-12-31 | CN¥3.48 | CN¥169.54 | x |
| 2021-12-31 | CN¥4.25 | CN¥169.54 | x |
| 2022-12-31 | CN¥4.35 | CN¥169.54 | x |
| 2023-12-31 | CN¥4.17 | CN¥169.54 | x |
| 2024-12-31 | CN¥6.10 | CN¥169.54 | x |
| 2025-12-31 | CN¥7.85 | CN¥169.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fujian Wanchen Biotechnology Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 90.65%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.61%
- • Asset Turnover: 5.12x
- • Equity Multiplier: 6.77x
- Recent ROE (90.65%) is above the historical average (23.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 26.74% | 20.44% | 0.69x | 1.90x | CN¥57.71 Million |
| 2020 | 23.99% | 21.36% | 0.68x | 1.64x | CN¥56.06 Million |
| 2021 | 3.59% | 5.39% | 0.50x | 1.32x | CN¥-41.82 Million |
| 2022 | 7.14% | 8.69% | 0.46x | 1.80x | CN¥-19.08 Million |
| 2023 | -12.85% | -0.89% | 2.37x | 6.08x | CN¥-147.46 Million |
| 2024 | 26.73% | 0.91% | 4.46x | 6.61x | CN¥183.71 Million |
| 2025 | 90.65% | 2.61% | 5.12x | 6.77x | CN¥1.20 Billion |
Industry Comparison
This section compares Fujian Wanchen Biotechnology Co. Ltd's net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $1,299,335,226
- Average return on equity (ROE) among peers: 3.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fujian Wanchen Biotechnology Co. Ltd (300972) | CN¥3.42 Billion | 26.74% | 2.14x | $4.82 Billion |
| ShenZhen Kondarl Group Co Ltd (000048) | $82.08 Million | -109.08% | 15.62x | $1.43 Billion |
| Guangdong Guanghong Holdings Co Ltd (000529) | $2.09 Billion | 4.06% | 0.45x | $415.17 Million |
| Hunan Zhenghong Science and Technology Develop Co Ltd (000702) | $621.75 Million | 5.39% | 0.49x | $285.06 Million |
| Hefei Fengle Seed Co Ltd (000713) | $1.94 Billion | 9.42% | 0.40x | $762.73 Million |
| Luoniushan Co Ltd (000735) | $182.12 Million | 17.91% | 0.39x | $1.00 Billion |
| New Hope Liuhe Co Ltd (000876) | $1.37 Billion | 8.75% | 0.69x | $4.72 Billion |
| Yuan Longping High-tech Agriculture Co Ltd (000998) | $1.74 Billion | 10.72% | 1.21x | $1.93 Billion |
| Dongrui Food Group Co Ltd (001201) | $1.20 Billion | 56.67% | 0.45x | $551.49 Million |
| Jiangxi Sunshine Dairy Co Ltd (001318) | $581.46 Million | 18.05% | 0.28x | $471.53 Million |
| Shandong Denghai Seeds Co Ltd (002041) | $3.19 Billion | 11.57% | 0.35x | $1.33 Billion |
About Fujian Wanchen Biotechnology Co. Ltd
Fujian Wanchen Biotechnology Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, production, and sale of edible fungi in China and internationally. The company offers enoki and golden enoki, white jade, crab, seafood, deer antler, oyster, and other mushrooms products, as well as flammulina velutipes, hydrangea edulis, and pleurotus eryngii. It is also inv… Read more